Anchor secures $480 million GPCR deal
This article was originally published in Scrip
Ortho-McNeil-Janssen Pharmaceuticals, the Johnson & Johnson company, has signed a collaboration and licence agreement with Anchor Therapeutics to enhance its ability todevelop G protein coupled receptor (GPCR)-targeted therapeutic compounds. The deal gives J&J access to Anchor's pepducin technology which it says represents a new approach to modulating GPCR signal transduction. GPCRs, the largest class of pharmaceutical targets, are notoriously intractable owing to their instability when taken out of their transmembrane localities.